TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31994022
Drug: ACT‐709478 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐709478 30 mg once daily for 12 days
Study: 31994022
Drug: ACT‐709478 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐709478 10 mg once daily for 12 days
Study: 31994022
Drug: ACT‐709478 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐709478 10, 30, and 60 mg for 7 days each, then 100 mg once daily for 8 days
Study: 31994022
Drug: ACT‐709478 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐709478 60 mg and 100 mg with midazolam
Study: 30574771
Drug: Combined sea
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sea salt-based oral rinse with xylitol
Study: 23881846
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with major hemorrhage included
Study: 23881846
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with major hemorrhage included
Study: 20797382
Drug: Desvenlafaxine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (100 or 200 mg/d)
Study: 18592146
Drug: Corticosteroids (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (methylprednisolone 40 mg/day)
Study: 9145453
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg/day)
Study: 18592146
Drug: Basal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal treatment (regular ipratropium bromide and beta‐2 agonist as needed) + placebo CS + placebo NAC
Study: 18592146
Drug: Basal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal treatment + placebo CS + N-acetylcysteine (600 mg/day)
Study: 14584228
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review and discharge counselling (Intervention group)
Study: 10922430
Drug: Front-loaded alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Front-loaded alteplase (up to 100 mg)
Study: 8757514
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of outpatient maintenance treatment
Study: 30902918
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg once daily, 2 weeks on/1 week off)
Study: 30902918
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg once daily, 4 weeks on/2 weeks off)
Study: 18448745
Drug: CDB-2914 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 10 mg daily (T1)
Study: 18448745
Drug: CDB-2914 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 20 mg daily (T2)
Study: 12559539
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.03 U/kg per day)
Study: 9349571
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) 200 microg daily for 12 months
Study: 2878812
Drug: Diphenhydramine (DPH)
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine (DPH) 50 mg b.d.
Study: 2878812
Drug: Temelastine (SKF)
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temelastine (SKF) 100 mg b.d.
Study: 26964731
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg sc daily
Study: 22437412
Drug: Non-renin-angiotensin-aldosterone system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-renin-angiotensin-aldosterone system (non-RAASi)-based therapy
Study: 17302259
Drug: Lamivudine therapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine therapy for 6-12 months
Study: 8888166
Drug: Dry mopping
Normalized name: 8-MOP
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dry mopping with topical and systemic antibiotics and topical steroids
Study: 1410148
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of 6 nights of 0.50 mg triazolam
Study: 1410148
Drug: Tapered discontinuation
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapered discontinuation (3 nights of 0.50 mg, 2 nights of 0.25 mg, and 1 night of 0.125 mg triazolam)
Study: 23390923
Drug: Intravenous t-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous t-PA alone
Study: 19000581
Drug: recombinant birch
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant birch pollen allergen vaccine (rBet v 1)
Study: 12875064
Drug: Kidney-tonifying prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney-tonifying prescription and routine western drugs
Study: 11794070
Drug: WHO formula
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Hand Sanitizer WHO Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO formula vaccines
Study: 11794070
Drug: FDA formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA formula vaccines
Study: 9124058
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge test with boiled egg and freeze-dried egg white
Study: 9124058
Drug: 20 min
Normalized name: wheat germ oil 20 minim ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 min patch test with raw egg white
Study: 9124058
Drug: 20 min
Normalized name: wheat germ oil 20 minim ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 min patch test with freeze-dried egg white
Study: 9124058
Drug: IgE antibody
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE antibody titers to egg white components
Study: 9124058
Drug: IgE antibody
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE antibody titers for ovomucoid fragments digested by pepsin, chymotrypsin, and trypsin
Study: 27873388
Drug: Sildenafil 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 60 mg three times a day
Study: 25421976
Drug: Dietary nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary nitrate (250 mL daily, as beetroot juice)
Study: 25421976
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mL daily, as nitrate-free beetroot juice)
Study: 24350416
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride (3 ml, 4.5 mg) dripped on ETT cuff
Study: 19038563
Drug: Laronidase 0.58
Normalized name: laronidase 0.58 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laronidase 0.58 mg/kg once-weekly intravenous infusion
Study: 19038563
Drug: Laronidase 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laronidase 1.2 mg/kg every 2 weeks
Study: 19038563
Drug: Laronidase 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laronidase 1.2 mg/kg every week
Study: 19038563
Drug: Laronidase 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laronidase 1.8 mg/kg every 2 weeks
Study: 19038563
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose regimens
Study: 11944733
Drug: Orthosiphon grandiflorus
Normalized name: Orthosiphon
DrugBank: Orthosiphon aristatus leaf (DB15838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthosiphon grandiflorus (OG) tea, 2 cups daily (2.5 g dry wt per tea bag)
Study: 11944733
Drug: Sodium potassium
Normalized name: SODIUM POTASSIUM ALUMINUM SILICATE
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium potassium citrate (SPC), 5-10 g in solution divided into three times a day
Study: 11944733
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (G1 and G2)
Study: 9598253
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhalation (5 and 10 ppm for two hours)
Study: 9598253
Drug: Prone positioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prone positioning + Almitrine (16 mg.kg-1.min-1)
Study: 9598253
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no further inhalation after initial NO)
Study: 29570044
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase standard dose of 0.9 mg/kg, up to a maximum of 90 mg, plus oral aspirin placebo
Study: 29570044
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase placebo plus active oral aspirin dose of 325 mg
Study: 24002278
Drug: FDC-based strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC-based strategy (n=1002) containing either (1) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 50 mg atenolol or (2) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide
Study: 21558462
Drug: Progesterone (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (90 mg vaginally) from 24 to 34 weeks of pregnancy
Study: 19850249
Drug: Combination-facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination-facilitated PCI (abciximab plus half-dose reteplase)
Study: 18499565
Drug: Primary PCI
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary PCI (abciximab administered immediately before the procedure)
Study: 18499565
Drug: Combination-facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination-facilitated PCI
Study: 16575661
Drug: Vacuum-assisted closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-assisted closure (V.A.C.)-therapy (group B)
Study: 8931286
Drug: Demand valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand valve system with oral-nasal mask
Study: 24684977
Drug: Sleep medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep medication (melatonin 14%, clonidine 9%)
Study: 15793183
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg, twice daily)
Study: 9435408
Drug: Raloxifene (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (400 mg) for 5 days in any phase of the menstrual cycle
Study: 9435408
Drug: Raloxifene (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (100 or 200 mg) for 28 days starting on day 3 of the cycle
Study: 18533940
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (13vPnC)
Study: 18533940
Drug: 23-valent plain
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent plain polysaccharide pneumococcal vaccine (23vPn)
Study: 1750603
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg epidural diamorphine
Study: 1750603
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg epidural diamorphine
Study: 1750603
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg epidural diamorphine with adrenaline 1/200,000
Study: 1750603
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg epidural diamorphine with adrenaline 1/200,000
Study: 1750603
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg epidural diamorphine with adrenaline vs 2.5 mg with adrenaline
Study: 30120138
Drug: Fremanezumab 225
Normalized name: FREMANEZUMAB 225 mg in 1.5 mL SUBCUTANEOUS INJECTION [AJOVY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fremanezumab 225 mg
Study: 30120138
Drug: Fremanezumab 675
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab 675 mg
Study: 28768076
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (HOPPS study)
Study: 22353604
Drug: i.v. ferric
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ferric carboxymaltose and subcutaneous erythropoietin (EPOFE arm)
Study: 22353604
Drug: i.v. placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. placebo and subcutaneous placebo (PLACEBO arm)
Study: 7635993
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day and Methadone 65-80 mg
Study: 26508834
Drug: Urinary kallidinogenase
Normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary kallidinogenase (UK) + conventional treatment
Study: 12753341
Drug: IFN-alpha2b plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2b plus ribavirin (600 mg/day) for 24 weeks and IFN-alpha2b alone for the next 24 weeks (R2: 48 patients)
Study: 12753341
Drug: Ribavirin dose
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin dose below 10.6 mg/kg/day
Study: 12753341
Drug: Ribavirin dose
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin dose over 10.6 mg/kg/day
Study: 9187104
Drug: Vorozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorozole (2.5 mg once daily for 7 days)
Study: 2880069
Drug: BN 52063
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN 52063 (80 mg)
Study: 2880069
Drug: BN 52063
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN 52063 (120 mg)
Study: 2880069
Drug: BN 52063
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN 52063 (80 mg and 120 mg)
Study: 30597865
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (PROHIGH: 2.9 g·kg−1·d−1)
Study: 30597865
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein diet (PROMOD: 1.8 g·kg−1·d−1)
Study: 26789541
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg silodosin once daily for 4 weeks
Study: 26789541
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin once daily for 4 weeks
Study: 1314260
Drug: Pindolol 15
Normalized name: pindolol 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 15 mg/day
Study: 23928836
Drug: Doxycycline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (20 mg orally, twice a day for at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days)
Study: 10867543
Drug: HDhep (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDhep (heparin anticoagulation)
Study: 9327192
Drug: Sulodexide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (250 lipoproteinlipase releasing units, two capsules twice daily for 176 days on average)
Study: 9327192
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg tablets, one tablet three times a day for 180 days on average)
Study: 3710287
Drug: Vaginal therapy
Normalized name: Monistat Simple Therapy Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal therapy with 500 mg metronidazole once a day for 7 days
Study: 3710287
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy with 400 mg metronidazole twice daily for 7 days
Study: 3710287
Drug: Vaginal therapy
Normalized name: Monistat Simple Therapy Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal therapy
Study: 29684433
Drug: Titrated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oxygen (initially 2 L/min, later adjusted to 4 L/min if tolerated)
Study: 29684433
Drug: Control oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oxygen (>10 L/min)
Study: 27821114
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (9,000 lux)
Study: 27821114
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light therapy (100 lux)
Study: 20430138
Drug: Dietary education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary education using Food Standards Australia and New Zealand's low-salt guideline of 120 mg sodium/100 g food
Study: 12966258
Drug: 0.5mg/kg ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg/kg ketamine administered epidurally (Kepi group)
Study: 12966258
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine administered intravenously (Kiv group)
Study: 12966258
Drug: 10ml normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml normal saline administered epidurally (Ctr group)
Study: 8772558
Drug: Alendronate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (40 mg daily for 6 months)
Study: 8772558
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg daily for 6 months)
Study: 1334248
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g daily of oatbran
Study: 6397334
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pivmecillinam plus 250 mg pivampicillin twice daily for 5 days
Study: 6397334
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg amoxycillin plus 125 mg clavulanate 3-times daily for 5 days
Study: 19458488
Drug: VCL‐AB01 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCL‐AB01 (0.2 mg)
Study: 19458488
Drug: VCL‐AB01 (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCL‐AB01 (0.6 mg)
Study: 19458488
Drug: VCL‐AB01 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCL‐AB01 (2 mg)
Study: 19458488
Drug: VCL‐AB01 (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCL‐AB01 (0.6 mg) in nonhuman primates
Study: 11747385
Drug: Prophylactic use
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic use of beta-adrenergic blockers
Study: 2905252
Drug: Roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate 150 mg post cenam nocte (PCN)
Study: 2905252
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg post cenam nocte (PCN)
Study: 2905252
Drug: Roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate 300 mg post cenam nocte (PCN)
Study: 24481570
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean final dose 14.4 mg/day)
Study: 19577277
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) chemotherapy (at least 5 cycles)
Study: 30873623
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic treatment
Study: 11222822
Drug: Various drugs
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drugs used for disease control during pregnancy
Study: 9221559
Drug: Peroral chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral chemotherapy (Hydroxyurea or Busulphan)
Study: 2139409
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d Gallopamil (group 1)
Study: 2139409
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d Metoprolol (group 2)
Study: 2139409
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Atenolol and 20 mg Nifedipine daily (group 3)
Study: 2139409
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Acebutolol plus 20 mg Nifedipine daily (group 4)
Study: 2139409
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Atenolol plus 10 mg Enalapril daily (group 5)
Study: 7247639
Drug: Combined pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacotherapy and behavior therapy
Study: 2613427
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy alone
Study: 31567411
Drug: Oral fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fosfomycin monotherapy for uncomplicated UTI and bacterial prostatitis
Study: 31567411
Drug: Intravenous fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosfomycin in combination with other agents
Study: 26775373
Drug: Tramadol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (75 mg/day)
Study: 26775373
Drug: Tramadol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol + Gabapentin (75 mg/day tramadol + 900 mg/day gabapentin)
Study: 25881758
Drug: Control (waiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (waiting list under drug treatment)
Study: 24311316
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 500 mg/day + AB
Study: 18647982
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg adjustable to 100 mg before sexual activity)
Study: 14740953
Drug: Monovalent live‐attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent live‐attenuated dengue virus (DENV) vaccine candidates
Study: 10674459
Drug: Gadodiamide injection
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide injection at a dosage of 0.1 mmol/kg body weight
Study: 9846855
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A (200,000 IU; 100,000 IU if aged <12 mo)